| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | cluster of differentiation 38, cyclic ADP ribose hydrolase |
| Product Type | |
| Shipping | |
| Species | |
| Storage | |
| UniProt # |
Scientific Background
CD38 (cyclic ADP-ribose hydrolase 1, ADPRC1) is a glycoprotein and ectoenzyme which plays an important role in regulating intracellular calcium. CD38 is a highly attractive target antigen for immunotherapy because it is highly expressed on multiple myeloma cells, and at relatively low levels on normal lymphoid and myeloid cells. Expression of CD38 has also been associated with HIV infection, leukemia, and type II diabetes mellitus. CD38 CAR-T is a T cell product engineered by retroviral transduction to express a fully human CD38-specific CAR (chimeric antigen receptor). In 2015, the FDA approved daratumumab (Darzalex), a breakthrough therapy drug targeting CD38, for the treatment of multiple myeloma.
Product Description
CAR T-Cell TherapyRecombinant clonal stable CHO cell line constitutively expressing full length human CD20 protein, also known as MS4A1 (Genbank #NM_152866). Surface expression of CD20 was confirmed by flow cytometry. Each stable clonal cell line was selected for different levels of CD20 expression (High, Medium) to mimic different stages of cancer target cells with various CD20 expression levels.
Product Specifications
| Host Cell Line | CHO |
|---|---|
| Host Species | Hamster |
| Transfection Method | Lipofectamine 2000 |
| Supplied As | Each vial contains ~ 2 x 10^6 cells in 1 ml of 10% DMSO in FBS. |
| Harmonized Tariff Code | 3002-5900 |
Quality Control & Validation
✓ Mycoplasma-TestedThis cell line has been screened using the MycoAlert™ Mycoplasma Detection Kit (Lonza, #LT07-118) to confirm the absence of Mycoplasma contamination. MycoAlert Assay Control Set (Lonza, #LT07-518) was used as a positive control.
Usage Notes
See data sheet for detailed culturing and assay protocol.
Safety & Handling
⚠ Avoid freeze/thaw cycles.
Regulatory Information
License Disclosure
Related Products
Related Products: Cat. #100346, 71277
Required Accessories: Cat. #79539,60186,79796
This product is engineered on a CHO background (Human origin). The CHO host was selected for its compatibility with stable transfection and the target pathway or assay type. Consult the product datasheet for passage number guidance and recommended culture media.
This product is classified as BSL-1. Standard microbiological practices (gloves, lab coat, eye protection) are sufficient. No specialized containment facility is required beyond a clean bench. Consult your institutional IBC for GMO registration requirements.
Yes. This cell line has been screened using the MycoAlert™ Mycoplasma Detection Kit (Lonza, #LT07-118) to confirm the absence of Mycoplasma contamination. MycoAlert Assay Control Set (Lonza, #LT07-518) was used as a positive control. We recommend that you independently confirm mycoplasma-negative status after receipt and periodically during routine culture using a validated detection kit.
Store this product at Liquid Nitrogen. Specifically: Store in liquid nitrogen immediately upon receipt. Transfer cells from dry-ice shipping to the recommended storage immediately upon receipt. Avoid repeated freeze-thaw cycles, which reduce viability and may alter expression characteristics.
Yes, a license is required (Yes). Purchase of this cell line grants a time-limited research-use license for use in your immediate laboratory only. This license does not permit redistribution, sub-licensing, transfer to other institutions, or commercial use. Refer to the License Disclosure section on this page or contact BPS Bioscience for details regarding modifications or commercial licensing.
This stable cell line was generated using Lipofectamine 2000 for transgene delivery into the parental host. The stably integrated cells were selected using the appropriate resistance marker and verified for expression prior to cryopreservation.
Can't find the cell line you need—or require a custom engineered model for your study? We offer end-to-end support for diverse research needs, including:
- Cell line sourcing and selection (species, tissue, and disease model matching)
- Stable cell line engineering (overexpression, knockdown, knockout via CRISPR/Cas9, shRNA, sgRNA)
- Reporter gene integration (GFP, RFP, luciferase, fluorescent/bioluminescent constructs)
- Genome editing and knockin (point mutations, tagged endogenous proteins, conditional alleles)
- Inducible expression systems (Tet-On/Off and regulatable constructs)
- Drug resistance marker selection (puromycin, G418, hygromycin, and others)
- Custom growth and media optimisation for specific assay requirements
- Scale-up production for high-throughput screening campaigns
- Authentication and QC services (STR profiling, mycoplasma testing, viability assessment)
Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.
- van de Donk, NW, et al. Monoclonal antibodies targeting CD38 in hematological malignancies and beyond. Immunological Reviews. 2016 Mar; 270: 95-112 2. Drent, E, et al. Pre-clinical evaluation of CD38 chimeric antigen receptor engineered against T cells for the treatment of multiple myeloma. Haematologica. 2016 May; 101 (5): 616-625 3. Sanchez, L, et al. Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma. Journal of Hematology & Oncology. 2016 Jun; 9: 51